PURPOSE The phase III KEYNOTE-048 (ClinicalTrials. gov identifier: NCT02358031) trial of
pembrolizumab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma …

PURPOSE Pembrolizumab and pembrolizumab-chemotherapy demonstrated efficacy in
recurrent/metastatic head and neck squamous cell carcinoma in KEYNOTE-048. Post hoc …

Purpose Treatment with pembrolizumab, an anti–programmed death-1 antibody, at 10
mg/kg administered once every 2 weeks, displayed durable antitumor activity in …

Background Pembrolizumab is active in head and neck squamous cell carcinoma (HNSCC),
with programmed cell death ligand 1 (PD-L1) expression associated with improved …

Background: KEYNOTE-048 was an open-label, randomized phase 3 study of P or P+
chemotherapy (C) vs EXTREME (E) as first-line systemic therapy for R/M HNSCC …

6000 Background: KEYNOTE-048 is a phase 3 study of P or P+ chemo (C) vs EXTREME (E)
as 1L therapy for R/M HNSCC (NCT02358031). At the second interim analysis (IA2), P …

PURPOSE CheckMate 651 (ClinicalTrials. gov identifier: NCT02741570) evaluated first-line
nivolumab plus ipilimumab versus EXTREME (cetuximab plus cisplatin/carboplatin plus …

LBA6008 Background: Pembrolizumab (MK-3475) is a humanized monoclonal antibody that
blocks interaction of PD-1 with its ligands, PD-L1 and PD-L2, thereby promoting activity of …

Background Patients with recurrent or metastatic squamous cell carcinoma of the head and
neck have few treatment options. We aimed to assess the safety, tolerability, and antitumour …

Background Second-line treatment options for advanced head and neck squamous cell
carcinoma (HNSCC) are limited. The phase Ib KEYNOTE-012 study evaluated the safety …